Depletion of calpastatin, an endogenous CAPN1 inhibitor which is encoded by a gene deleted in del(5q) MDS, increased the expression of CAPN1 and enhanced the sensitivity of del(5q) MDS to lenalidomide [61]. Here, CAPN1 is linked to myelodysplastic syndrome.